The CS-treated group displayed a low skin symptom severity score, a low serum IgE level, and alleviation of histopathological features such as movement of inflammatory cells and epidermis hypertrophy, compared to those in the control group. The gene discussed is IGHE; the disease is Cowden syndrome 1.